Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
The evaluation largely aligns with label content for core mechanism and specific indications (especially SN-38 MOA and gemcitabine-progressed metastatic pancreatic cancer), but safety-related elements (boxed warnings, contraindications), dosing specifics, and use in special populations are under-addressed or omitted.
Category Scores
Accurate Statements
Onivyde is a liposomal formulation of irinotecan.
11, 12.1
Irinotecan is converted into its active metabolite SN-38.
12.1
SN-38 is a potent topoisomerase I inhibitor.
12.1
SN-38 binds to the complex formed between topoisomerase I and DNA.
12.1
This binding stabilizes the complex.
12.1
This stabilization prevents the re-ligation of the DNA strand breaks.
12.1
The liposomal encapsulation of irinotecan in Onivyde alters its pharmacokinetic profile.
12.1
Onivyde is approved for the treatment of adult patients with metastatic pancreatic adenocarcinoma after gemcitabine-based therapy.
1
Onivyde is formulated with irinotecan hydrochloride trihydrate and is a liposomal dispersion for intravenous use.
11
Unsupported Statements
Onivyde is a chemotherapy drug used to treat certain types of cancer.
Label specifies metastatic pancreatic adenocarcinoma indications; broad phrasing does not precisely match label scope.
Its mechanism of action involves the release of irinotecan.
Label MOA describes SN-38–mediated topo I inhibition; no described 'release' mechanism.
The liposomal formulation allows for a slower release of irinotecan into the bloodstream.
Explicit slower-release description is not clearly stated in labeled MOA or PK sections.
This sustained release can lead to a longer exposure of cancer cells to the active drug and its metabolite, SN-38.
Label discusses exposure in PK/SN-38 context but does not state a direct sustained-release exposure claim to cancer cells.
This formulation can potentially alter the drug's distribution and toxicity profile.
Label notes altered PK and potential distribution/toxicity consequences in general terms, but exact phrasing is not explicit.
Onivyde is often used in combination with fluorouracil and leucovorin in a regimen known as mFFOLFIRINOX, following disease progression on gemcitabine-based therapy.
Label mentions combination with FU/LV after gemcitabine progression but does not name the regimen 'mFFOLFIRINOX' or state 'often' use.
Contradictions
Important Omissions
Boxed warnings related to neutropenia and diarrhea.
Importance:
High
Contraindications (e.g., hypersensitivity, liposomal excipients).
Importance:
High
Dosing/dose modification guidance and hepatic/renal impairment adjustments.
Importance:
High
Pregnancy risk and use in pediatric populations.
Importance:
High
Storage and handling details.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Known label safety risks (neutropenia, diarrhea) are not fully addressed in the claims; significant safety information is omitted.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Missing or incomplete coverage of boxed warnings, contraindications, dosing specifics, and use in special populations; some MOA statements should avoid implying a release mechanism.
Suggested Improvement
Incorporate explicit Boxed Warning statements (neutropenia and diarrhea) with management steps; include contraindications; provide clear dosing guidance and dose adjustments; address pregnancy and pediatric use; ensure MOA descriptions reflect label language (focus on topo I inhibition by SN-38) without implying drug release.